SIDE EFFECT | TRIAL | INCIDENCE |
---|---|---|
Injection site reactions | SPS | 48% in vaccinated group, 17% in placebo group; NNH = 3 |
|
| |
Headache | SPS | 1.4% in vaccine group, 0.9% in placebo group; NNH = 167 |
Serious adverse events | SPS | 1.4% in both vaccine and placebo groups; similar distribution |
Hypersensitivity reactions (including anaphylactic reactions, fever, rash, and lymphadenopathy at the injection site) | Postmarketing surveillance | Uncommon to rare |
NNH—number needed to harm, SPS—Shingles Prevention Study.
Data from the Zostavax product monograph.10,26